5,6,7,8-四氢咪唑并[1,2-a]吡嗪盐酸盐 | 1187830-84-7

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 5,6,7,8-四氢咪唑并[1,2-a]吡嗪盐酸盐
• 中文别名: 5,6,7,8-四氢咪唑并[1,2-A]吡嗪盐酸盐
• 英文名称: 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine hydrochloride
• 英文别名: 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;hydrochloride
• CAS: 1187830-84-7
• 化学式: C₆H₉N₃*ClH
• 分子量: 159.618
• InChiKey: HHISCLFBXNGLCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.41
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-chloro-5-(2-(cyclopentylmethyl)oxazol-5-yl)picolinonitrile 、 5,6,7,8-四氢咪唑并[1,2-a]吡嗪盐酸盐 在 chloro-(2-dicyclohexylphosphino-2’,6’-diisopropoxy-1,1‘-biphenyl)[2-(2-aminoethyl)phenyl] palladium(ll) methyl-tert-butyl ether adduct 、 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 5-(2-(cyclopentylmethyl)oxazol-5-yl)-6-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)picolinonitrile
  参考文献：
  名称：

  [EN] 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
  [FR] MODULATEURS ALLOSTÉRIQUES DE 5-(PYRIDIN-3-YL)OXAZOLE DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE

  摘要：

  提供了含有5-(吡啶-3-基)噁唑化合物的组合物，这些化合物的组合物以及这些组合物在潜在预防或治疗M4肌胆碱受体参与的疾病中的用途。

  公开号：

  WO2019000238A1

文献信息

• Inhibitor of cox
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040157891A1

  公开（公告）日：2004-08-12

  A compound of the formula (I): 1 wherein R 1 is cycloalkyl, etc; R 2 is (lower)alkoxy, etc; R 3 is (lower)alkylene, etc; R 4 is (lower)alkylene, etc; R 5 is hydroxy, etc; X is “O”, “S”, “SO”, or “SO 2 ”; Y is “CH” or “N”; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament.

  一种具有以下式（I）的化合物：其中R1是环烷基等；R2是（较低）烷氧基等；R3是（较低）烷基烯基等；R4是（较低）烷基烯基等；R5是羟基等；X为“O”、“S”、“SO”或“SO2”；Y为“CH”或“N”；n为0或1；或其药学上可接受的盐，可用作药物。
• [EN] OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE<br/>[FR] DERIVES D'OXAZOLE UTILISES COMME INHIBITEURS DE LA CYCLO-OXYGENASE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004065374A1

  公开（公告）日：2004-08-05

  A compound of the formula (I): wherein R1 is cycloalkyl, etc; R2 is (lower)alkoxy, etc; R3 is (lower)alkylene, etc; R4 is (lower)alkylene, etc; R5 is hydroxy, etc; X is '0', 'S', 'SO', or 'S02'; Y is 'CH' or 'N'; n is 0 or 1; or pharmaceutically acceptable salts thereof, which are useful as a medicament.

  其中R1是环烷基等；R2是（较低）烷氧基等；R3是（较低）烷基等；R4是（较低）烷基等；R5是羟基等；X是'0'，'S'，'SO'或'SO2'；Y是'CH'或'N'；n为0或1；或其药学上可接受的盐，可用作药物。
• 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10981902B2

  公开（公告）日：2021-04-20

  The present invention is directed to 5-(pyridine-3-yl)oxaxole compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

  本发明涉及 5-(吡啶-3-基)氧杂吲哚化合物，它是 M4 蕈样乙酰胆碱受体的异位调节剂。本发明还涉及本文所述化合物在潜在治疗或预防涉及 M4 肌 肉碱乙酰胆碱受体的神经和精神疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及 M4 蕈样乙酰胆碱受体的此类疾病中的用途。
• 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3644990A1

  公开（公告）日：2020-05-06
• [EN] 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTÉRIQUES DE TYPE 5-(PYRIDIN-3-YL)OXAZOLE DU RÉCEPTEUR MUSCARINIQUE M4 D'ACÉTYLCHOLINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019005589A1

  公开（公告）日：2019-01-03

  The present invention is directed to 5-(pyridine-3-yl)oxaxole compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.